Arkema S.A. (AKE) Earnings Call Transcript
November 7, 2025
Earnings Call Speaker Segments
Hello, and thank you for joining Arkema's conference call covering third quarter 2025 results and outlook. Please note that this call is being recorded. It will run in a listen-only mode, and following the presentation you'll have a chance to ask questions by pressing star and one on your touchtone telephone. I'll now turn things over to Thierry Le Hénaff, Chairman and Chief Executive Officer. Sir, please go ahead.
Thanks so much. Morning, everyone. Glad to have you on the Arkema Q3 2025 results conference call. Joining me are Marie-José Donsion, our CFO, along with the investor relations team. We've posted a set of slides to accompany this call, and you can find them on our website. As we always do, I'll open with a few remarks on the quarter's highlights, then hand things over to Marie-José for the financials. Once the presentation wraps up, we'll be here, as usual, to take your questions. Let me begin with the economic environment, which stayed challenging, as you're aware. Over the summer we saw softer trends in the U.S. than expected. That weaker demand likely reflects continued uncertainty surrounding tariffs as well as friction as supply chains adjust. Europe and Asia, meanwhile, are tracking in line with what we've observed since the year began. Europe sits at fairly low levels, while Asia continues to show positive momentum, especially in China. The currency headwind was also a bit stronger than in Q2. Even against this difficult macro backdrop, our growth pockets, which sit at the heart of Arkema's strategy, posted substantial growth. In fact, sales rose 20% across several key markets, specifically batteries, sports, 3D printing, healthcare, and new-generation fluorospecialties with low global warming potential.
That positive momentum is helping the ramp-up of our major project, currently on slide seven, but taken together, it clearly wasn't enough to counter the strong macro headwinds in the third quarter. When we reported Q2 results, we told you this major project ought to deliver EUR 50 million of additional EBITDA in 2025 compared with 2024. I'm pleased to say we've reassessed progress, and we can now put the impact at EUR 60 million. That contribution rests mainly on strong momentum in PVDF for batteries, biosourced Pebax in sports, and 1233zd fluorospecialties in building insulation. PIAM has also grown well since the year began, helped by new smartphone models, and Dow's flexible packaging adhesives are beginning to contribute. This is certainly below the EUR 100 million initially estimated, which reflects the tough environment. Even so, the project has shown good momentum, and the setup for 2025 is encouraging. As you know, these projects are already fully financed and so sit within our capital employed, with only a limited contribution to the P&L so far. On that point, the group will gain roughly 2.5 points of ROCE from this project over the coming years, on top of the improvement in the cycle, which will benefit everyone.
We can also note that two new plants started up in Q3 in the U.S., both on budget and on schedule. The new 1233zd unit—a fluorospecialty with low emissive impact, used for building insulation or thermal management—and our new DMDS capacity for refining and biofuels, with an impact on earnings still limited in 2025. Beyond that, mechanical completion has been reached at the new refined clear transparent polyamide plant. This unit, downstream of the polyamide 11 plant in Singapore, should be operational in the first quarter of 2026. Given the tough environment, I want to stress that everything is fully mobilized every day to best manage the current economic and geopolitical context. We launched a number of cost-cutting initiatives, as shown on slide three, and we're on track to deliver the targeted EUR 100 million of fixed and variable cost savings by year-end. Cost alignment will continue, and we strive to, again, offset inflation in 2026. Arkema also stays disciplined in capital allocation. You can see that we made progress in working capital management and delivered EUR 200 million recurring cash flow compared to last year, despite lower earnings. This cash generation is fully reflected in the reduced debt, maintaining a robust balance sheet.
Arkema is going to lower CapEx again next year, bringing it to EUR 600 million, and at the same time we'll keep optimizing working capital. Even with all the efforts from Arkema's teams, EBITDA fell to EUR 310 million. If you look at results by segment, you can see the different profiles of each product line. Adhesive Solutions and Advanced Materials are more resilient, with earnings hit by weaker demand, while net pricing declined only slightly. By contrast, Coating Solutions saw more volatility tied to the low cycle in upstream acrylics, and the old-generation fuel gases in Intermediates posted a seasonally lower result. I've already mentioned the ramp-up of our major project, which reflects how we're executing our growth strategy, and also our capacity to handle two tasks in parallel. We're focused on optimizing operations for the short term, but at the same time we're securing our growth potential for the long term. Both of these get us ready for the new year, when the macro environment will be more supportive again. As I stressed earlier, we pursue a strategy centered on five identified high-growth markets, where we're constantly searching for new opportunities. With that in mind, I'm pleased to announce that we'll broaden our potential in the appealing advanced electronics market by adding a new structured platform dedicated to data centers.
Slide five of our Q3 presentation has already covered the specifics for you. We believe this strong market offers substantial growth opportunities when we commit joint initiatives to it, even if we are beginning from a fresh base. I would also like to highlight how well Arkema has done in Asia's battery market. Our wager on LFP batteries is plainly paying off, and our approach of growing the asset base through modest CapEx in China, Europe, and the U.S. has proven pertinent, which leaves us well placed to expand within this vibrant market. We just opened a new lab devoted to next-generation batteries, applying an inventive dry coating method for electrodes that cuts battery production costs considerably and shrinks its carbon footprint at the same time. This breakthrough shows that PVDF's long-term growth potential is still substantial, and it delivers a premium margin when you aim, as we do, at the high end of the range. I will now pass things to Marie-José, who can give you further details or a deeper review of the financials before we turn to the outlook at the close of the presentation.
Thanks, Thierry, and good morning to all of you. I'll begin with Arkema's revenues. Q3 sales came to EUR 2.2 billion, a decline of 8.6% compared with the same period last year. A currency effect of -3.9% weighed on those sales, driven mainly by the US dollar's weakening against the Euro, and also by other currencies, among them the Chinese yuan and the Korean won. Volumes fell 2.5%, which reflects the softer demand seen in the U.S. during the summer as well as the broadly weak demand backdrop in Europe. Conversely, we kept benefiting from positive momentum in Asia, and in China especially, largely on the back of high-performance polymers. The price effect stood at -3.7%, essentially due to the acrylic cycle and old generation refrigerant gases. Every other activity posted a more contained price decline of 1.3%, with net pricing slightly negative. The gain from cheaper raw materials feeds through the supply chain gradually. Q3 EBITDA reached EUR 310 million, with the currency effect accounting for roughly EUR 15 million negative. Turning to segment performance, Adhesives EBITDA mirrored soft demand in industrial adhesives and a disappointing summer in the U.S., particularly in flexible packaging and construction. In contrast, the construction business expanded in Asia on the strength of positive momentum in efficient buildings and stayed broadly flat in Europe.
Bostik's results keep being underpinned by the efficiency efforts we have underway and by our pricing discipline. And then, the Dow adhesives integration added only a modest amount this quarter, because of weakness in the U.S. market in particular. Over in Advanced Materials, EBITDA was basically hit by lower volumes in performance adhesives. Those were squeezed by soft demand in both Europe and the U.S., along with the restructuring of our Jarrie site in France in hydrogen peroxide. Conversely, volumes for high-performance polymers held steady, helped by robust growth in Asia. The Advanced Materials segment's margin stayed broadly at a healthy level, 18.8%, and HPP kept its sturdy 20% margin. In Coatings, EBITDA was mainly affected by the downcycle in upstream acrylics. Sales fell in the U.S., especially in the construction and decorative paints markets. So the segment's performance came in significantly below last year. And finally, Intermediate's EBITDA reflected the usual third-quarter seasonality plus the effect of regulatory changes in the U.S. and Europe for refrigerant gases. Depreciation and amortization came to EUR 168 million. That figure included amortization of new production units that came on stream during 2024 and also in 2025.
That gave us recurring EBIT of EUR 142 million, with a REBIT margin of 6.5%. Non-recurring items came to EUR 48 million. Within that figure you have the usual EUR 35 million of PPA depreciation plus EUR 13 million of one-off charges, in particular refreshing costs tied to reorganizing our hydrogen peroxide business in France. Financial expenses were EUR 33 million. That is up compared with last year, mainly because our bonds cost more, and also because cash we have invested earned less interest. As a result, Q3 adjusted net income came in at EUR 78 million, equal to EUR 1.04 per share. Turning to cash flow and net debt, Arkema generated solid cash flow in Q3, as you saw, with recurring cash flow of EUR 207 million. That mirrors our ongoing efforts to keep working capital under tight control and also to bring CapEx down relative to last year. The working capital ratio on annualized sales was 17.3%, and capital expenditure totaled EUR 131 million, consistent with our EUR 650 million target for the full year 2025. Net debt is EUR 3.4 billion, including EUR 1.1 billion of hybrid bonds. Net debt over last 12 months EBITDA is roughly 2.6x.
Also worth noting, we're still refinancing the bonds that come due in 2026 — in September we issued a EUR 500 million green bond, which carries an eight-year maturity and a 3.5% annual coupon. That move has let us push our debt maturity out to 4.6 years. Thanks for listening, and now I'll turn things back to Thierry for the outlook.
Thank you, Marie-José. As we head into Q4, the macroeconomic backdrop is still difficult, characterized by poor visibility and soft demand across the U.S. and Europe — so that comes as no surprise. Against this backdrop, as I've already noted, optimizing for the short term through work on fixed costs, CapEx, and working capital stays among our highest priorities. As mentioned, we remain on track to deliver roughly EUR 100 million in fixed and variable cost savings in 2025. To be more specific, our many fixed-cost initiatives should allow us to offset inflation in both 2025 and 2026. Simultaneously, we keep building Arkema for the future. That matters a great deal. We do so by sustaining our efforts in R&D and in sales and marketing, focused on the key attractive markets the group has identified, backed by the major projects you know well. Taking into account the macro environment, which remains challenging, and demand in the U.S. that is softer than expected — at least for now — we are targeting an EBITDA of between EUR 1.25 billion and EUR 1.3 billion in 2025, with a midpoint broadly in line with consensus, and recurring cash flow of approximately EUR 300 million. Thank you very much for your attention.
Marie-José and I are definitely prepared to take whatever questions you may have.
Thanks. To ask a question by phone, hit star and one on your keypad. Should you want to take your question back, press star and two. Once more, press star and one on your telephone to join the question queue, then wait until your name is called. Our first question comes from Martin Roediger at Kepler Cheuvreux. You have the floor.
Yes, hello and good morning. If I may, I have three questions. Thierry, the first one is for you. On the reason for this extra guidance reduction this year, it seems your concern about the U.S. market is growing, particularly the weaker construction market there. How do you view the near-term prospects for U.S. construction? The remaining two questions go to Marie-José. Some other chemical companies have released bonus provisions in Q3, and some already in Q2. Have you done the same, and do you intend to in Q4? Is that included in the EUR 100 million of cost savings this year, which addresses both fixed costs and variable costs? We know that bonus falls under variable costs. Lastly, on the cost savings impact on your P&L, your SG&A costs rose in the Q3 quarter on quarter and year over year. Why don't we see the cost savings in your SG&A line? Thank you.
Alright Martin, thanks for the question. On the first point, the answer is no. What we're seeing today is that, yes, over the summer the U.S. came in weaker than expected. Not necessarily weaker than Europe, since Europe was already weak — but does that necessarily mean we've turned more pessimistic on the U.S. as we head toward midterm? I'd say this about the U.S.: we have long experience there, because it accounts for 35% of our total sales. What we've learned in the U.S. is that things move quite fast. That country is very agile, so you can get a quarter that disappoints, and then two quarters later it's heading the opposite way. I'll be cautious in my answer. We're only commenting on what we see in Q3. Our view is that Q4 will follow a similar pattern, but I'd be careful about extrapolating what that implies for the quarters after, because it's simply in the nature of the U.S. to react more quickly, and there we tend to see a bit more volatility than in other regions of the world. Marie-José?
On cost savings — and maybe stepping back a bit to restate our goal — the aim is essentially to achieve EUR 100 million in savings. I'd characterize that as 2/3 fixed cost and 1/3 variable cost. Looking at the fixed cost piece, the bonuses are of course included in that. That's been adjusted gradually over the course of the year, based on the revised guidance we provided to you. I don't expect any last-minute effect in Q4, I would say. It's been factored into the publications progressively. When you look at how things evolved year-on-year, what you basically see is a slight increase — meaning that at present we aren't fully offsetting inflation, though we are in fact offsetting it quite substantially. For Arkema, I put inflation on fixed costs at roughly EUR 60 million to EUR 70 million per year. Right now, we're clearly capping the impact of rising fixed costs at, I would say, only EUR 15 million in total. Clearly, we are generating — delivering — the effort needed to compensate for this inflation effect on a massive scale. I'm not sure why it seems invisible to you, but internally it's definitely visible when we look at our metrics. There's no particular effect from provisions, which, if you look at the balance sheet, are fairly stable across the period.
I hope that addresses what you asked.
All right, thanks a lot.
I might also add something for Marie-José here: when we talk about stripping out inflation for next year, what that really means is we’re factoring in the point Marie-José made — that a portion of this year’s savings comes from bonuses — and we’re aware that we’ll have to offset that in the following year, yet that’s simply how it works, and we’re up for the challenge.
Tom Wrigglesworth from Morgan Stanley has the next question. Go right ahead.
Good morning, everyone. Appreciate the presentation. I have two questions, if I may. The first concerns the data center presentation you gave, particularly the refrigerant gases. You mentioned foraying for chillers. What impact does that have on the market? Will it quickly tighten the existing supply of HFCs and HFOs? Second, regarding the immersive heaters, will that be a higher margin product than your current emissive refrigerant gas business? So that is a couple of questions there. Then, really at a kind of higher level, obviously, if I look at the bridges for all of this year, pricing is going down faster than raw materials. Is that a function of mix, i.e., you are losing higher value products more so than you are retaining raw material gains? Or are you having to give back price to hold on to volume? Thank you.
Alright, thank you, Tom, for asking that. It's quite a different kind of question. Let's start with data centers — if you look at page five of the presentation, you'll see this is, I'd say, our first real exchange with you on data centers. Just so you're aware, it doesn't cover what we're doing in batteries for data centers. What I mean is the stationary battery side, which sits within the battery platform. So when we talk about more than EUR 100 million in sales by 2030, starting from a base that today stands at roughly EUR 10 million by our first estimate — that's a significant increase — it excludes our battery work. As you pointed out, chillers will be a key element with the new generation of refrigerant. Sales there right now are very, very limited, but we see strong potential for low GWP fuel gas in chillers. That depends, as you know, on data center technology, but we see very good growth with good margins — though it's just one item out of six or seven. We also see growth in high-performance polymers. That could be PVDF, or it could be polyamide 11 for wire and cable.
There are also uses in flooring or waterproofing, ballistics included. Even direct-to-chip cooling can use it — PVDF and the like. So we have plenty of applications in that space, though as you said, HFO is definitely one piece of it. On pricing, it's actually interesting to dig into the details of what's going on there. We split out acrylics monomers and fuel gas, both of which see meaningful pricing effects. The first reflects the cycle; the second reflects how generation is evolving. You can't do an apples-to-apples comparison because of the quota mechanism. Intermediates clearly has a large — it certainly has a large effect on pricing. Beyond Intermediates, the effect is much smaller. Beyond acrylic monomers, it's smaller still. For Adhesive Solutions and Advanced Materials, net pricing is roughly neutral — a touch negative, but roughly neutral. Pricing itself sits at about -1%. Turning to raw materials, what's happening is that, as you know, with the supply chain you carry some stock, and it takes time for raw material to flow through the P&L. There's a bit of a lag between the pricing impact and the raw material.
Honestly, we have zero concern when it comes to Adhesive Solutions and Advanced Materials. There are certain cases where things are a little tougher — particularly in China, where pricing pressure exists — yet conversely, we're seeing favorable pricing elsewhere, among them our new business development carrying a premium price. As far as pricing goes for us, what has genuinely been the worry since the year began is refrigerant for the old generation along with acrylic monomers.
Appreciate it, Thierry. That's really useful.
I appreciate it.
Matthew Yates from Bank of America has the next question. Go ahead, please.
Morning, everyone. I have a couple of questions, if that's okay, and I'd like to build on what Tom asked regarding the data center. You mentioned it's really the first time you've brought this up. I'm just trying to get myself up to speed a bit. How far along are you commercially with some of these products? Have they been technically developed? Have customers qualified them? Are sales already being generated? Or would you say this is more of an ambition, with plenty of work still needed over the coming few years before these products actually reach the market and start bringing in revenue? That's my first question. For the second, I'm not sure whether this is for you, Thierry, or for Marie-José, but I wanted to ask about the dividend. As we know, Arkema traditionally had other strategic priorities, and the payout ratio on the dividend was fairly low. Against the free cash you're now generating of EUR 300 million, that's effectively 100%, and your leverage has been creeping up to three times. Could you give us a sense of how important that dividend is and how sustainable it is when you reach the end of the year and discuss it with the board?
Has this reached the stage where, absent a macro improvement, distributing such a large amount will cut into your strategic flexibility—whether you want to fund CapEx projects or M&A, or whatever else? I'd simply like to hear your thinking, your philosophy, regarding the dividend. Thank you.
Thanks, Matthew — that's clearly an important question. On data center, like I said, we have sales of a bit more than EUR 10 million, so that means this product already has commercial traction, and most of the products we're discussing are already developed. What takes time — and that's the reason we have a ramp-up through 2030 to get above EUR 100 million — does not, as I mentioned, factor in the PVDF for stationary batteries that serve data centers, which is not insignificant and is already fully commercial. On what sits outside, I'd say the technologies themselves have already reached a certain maturity. It's more about developing applications with qualification and so on. It will take the time it takes, knowing that in data centers the technology really keeps evolving, as you probably know, significantly. Even for you, there would already be matured sales in certain applications. Regardless, you need to work on new applications and new technology, and to adapt your products and your new business development to that. To answer your question — we're right in the middle of your question, I'd say.
There's a degree of commercial readiness with mature technologies, yet the applications themselves aren't fully mature. We have to ramp things up, and that's going to require a certain number of years. I believe it was mature enough for us to share the data center call with you, and we'll have the chance to return next year with much more detail on this data center topic, which, as I said, is joining the advanced electronics platform. On the dividend, to a certain extent, the answer lies within the question. The good news first is that conditions are absolutely perfect for us in specialty chemicals and in chemicals overall. Even so, with free cash flow, we cover the dividend. I think that's good news. You know that returning the dividend to shareholders is a very important policy for Arkema. The aim is to keep it sustainable. It has been so in the past. No year looks like the one before it. To keep it sustainable, beyond what I've just said, you could see that next year CapEx will be at EUR 600 million versus EUR 650 million this year. That's a difference. Our project will ramp up as well. I think we remain with that same idea of a sustainable dividend.
Naturally, that's a call the board has to make. As a rule, we'll hold that discussion ahead of presenting the full year results. That's how Arkema does things.
All right, thanks, Thierry.
The next question comes from Georgina Fraser at Goldman Sachs. Please go ahead.
Hello, and good morning. Thank you very much for taking my questions. I have two. It's good to talk with you, Thierry and Marie-José. My first question concerns HPP. We've observed a fair level of CapEx as well as the PIAM acquisition flowing into this division. I'd just like to hear from you how this division has performed relative to your expectations. Should we consider that utilization rates may currently be low? I'm just trying to get a sense of the upside potential here and perhaps why performance has been somewhat lackluster. My second question follows up a bit on the dividend or cash flow outlook question. EUR 600 million in CapEx next year remains quite high. Could you give us an idea of your maintenance CapEx and how much flexibility exists there if it were needed? Thank you.
Yes. All right. Thanks, Georgina. Hi there. Regarding your first question, first of all, looking at HPP, we've got four lines that are quite compelling. Those are PVDF, specialty fuel gases, polyamide 11, and PIAM. I'd say every one of these lines is a growth line — one where, as you pointed out, we've invested a substantial sum in development, in growth, in CapEx, and in acquisitions. Obviously, this year is a tough one for every chemicals company. HPP isn't shielded from that. As you were able to observe, and this forms part of advanced materials' performance, HPP has held up decently relative to what we're seeing elsewhere, yet it fell short of our expectations owing to the macro picture. The projects themselves are progressing at an okay pace, but the macro affects them too. At the start of the year, we had anticipated more from HPP. The encouraging part is that we believe all the strategic moves we've made with HPP were the correct ones, and that this line is surely among the most resilient within Arkema. The growth outlook, even though there have been some delays to a degree because of the macro, that growth outlook stays fairly substantial.
On utilization rate, it's clear that consistent with the macro picture, things are leaning toward the lower end. Keep in mind we're optimizing inventory too, as everyone is doing across the supply chain, from customers all the way to suppliers. Given that, we've also adjusted, let's say, the utilization rate at our site. We believe HPP will stay a bright spot for Arkema in the periods ahead. On CapEx, I don't agree with the view that CapEx is still quite high at EUR 600 million. To be transparent, since we talk with all of you, investors included, some tell us the opposite — that maybe it's a bit too low. For us, I think it's reasonable in this kind of environment to bring CapEx down to a level that remains relatively okay, without jeopardizing our mid- and long-term growth. Doing so would be a complete mistake. Some companies in chemicals did that in the past, and now they regret it. We try to stay consistent over the years. On the other hand, in 2024 we stood at EUR 750 million.
This year we're at EUR 650 million. Next year, EUR 600 million. I believe that's a sensible CapEx adjustment to reflect how the macro picture is evolving. As for the split between maintenance, modernization, legislation, and CapEx, I'd say we have roughly — yes, EUR 400 million of when we stood at EUR 650 million, we were at about 60, 60/40. That means it's EUR 400 million, yes, roughly EUR 400 million. What remains is really productivity and development CapEx, though those are on a smaller scale than what we've done over the past three years with the major projects.
Thanks.
Jean-Luc Romain from CIC Market Solutions has the next question. Go right ahead.
Hello there. <<inaudible>>. May I ask you something? Does it sound better at this point? Nope, we can't hear a thing.
Romain, would you mind moving a bit nearer to the mic, please?
I've got the microphone now.
There's another voice we can hear behind you.
Yes, okay.
All right. Perhaps we can take one more, and then we’ll return to you once your topic is sorted out.
All right — moving on to Chetan Udeshi from JPMorgan. Your line is open, go ahead.
Hi there, thanks for the question. Mine is a somewhat more philosophical one. From everything you've said, it sounds like your view is that this is largely a cyclical phenomenon in the sector, and for that reason you don't necessarily want to take any radical steps. Is that understanding correct? Because when I look at your numbers — and it isn't just Arkema, right? To be fair, it's the whole sector. Everyone is suffering from the same issue. A lot of the time, at least in my personal opinion, it gets blamed on demand weakness, which may or may not be the only reason. I'm just curious, from your perspective, do you not see any structural changes in the industry that would warrant more structural changes in how Arkema is set up? I mean, in terms of whether you need to have all of the businesses that you have within Arkema, or maybe it's better to monetize some of them given the multiple. Thank you.
Thanks for asking that. It's a fair question, at least in theory. Of what we're seeing right now, how much would you call short-term cyclical, and how much might be more structural? As you know, we've been in this business for 20 years, and honestly—you may have forgotten—those 20 years have brought major shifts across the world. At any given moment, things can go both ways, positive and negative. Whenever there's structural change, the downside always matches the upside one-for-one. Opportunities and challenges arrive together. That holds true now, and it held true over the past 20 years. So what we're observing now is a mix of—and by far the majority of what we're observing falls here—some cyclical issue tied to macro conditions, and it will recover. We're 100% convinced of that. Beyond that, there's some structural change that goes further. There's more, let's say, protectionism. There's more regionalization. There's more aggressiveness coming from Chinese competitors. Incidentally, we benefit from that too, since we're strong in China, and we've had quite a good year in China.
Sure, that's how the world works now. You have to stay agile and keep adapting all the time. Where I'd push back on your point is this idea of radical steps or anything like that. Take Arkema's portfolio as an example: 60% of the business that existed at the start has been divested. We transformed it entirely. We made acquisitions. That's simply part of business life for us, and we'll keep taking whatever steps make sense. We're constantly thinking, though obviously we don't necessarily share all of that thinking with all of you. No, I'd say our level of response is good. We genuinely try to handle both horizons simultaneously. One is very short-term — working on cost, working on cash — and thanks to the team, I think we're doing quite a great job there. At the same time, keeping in mind that the framework we operate in is shifting somewhat, we're moving to adapt to it. That's what we divested in recent years, the PMMA, and we acquired Ashland and PIAM. Even if those two aren't exactly where we'd have expected them to be in terms of ramp-up, I can tell you they're far more resilient than many businesses in chemicals.
Things are moving the right way. It takes time. I believe we're truly focused on the right topics, and we're doing what's necessary. That doesn't stop us from constantly asking whether a different development might make sense. No, no, we're aware of that. It's beneficial for us. I've always maintained that Arkema wouldn't be the Arkema it is today. The world was easy and lighter than if you'd had the same players as 20 years ago. I think the fact that disruption exists may cause us short-term pain, but we believe that over the long run, it creates opportunities for companies like ours—for companies that are reactive, agile, willing to question themselves, to seize new opportunities, and to make a difference compared with the other guys.
Alright, thanks so much.
Our next question comes from Emmanuel Matot at Oddo BHF. Emmanuel, please go ahead.
Hi Thierry, hi Marie-Josée. Three questions from me. First, with the U.S. customs tariff matter now resolved, do you believe we're nearing the trough of the cycle? What are your key customers over there saying to you? Given your choice to step up cost efforts, you seem quite wary about a recovery scenario for next year. Second, could you give us an update on PIAM? How is it performing in the present environment? And my final question: inventory at the end of September is flat in value versus the end of June, at EUR 1.3 billion. Does that imply cutting stock going forward will be very hard should demand fail to rebound? Thank you.
All right. As we said, it's clear we're in a low cycle. So where exactly do we stand? I think everyone needs to be humble about that. Analysts and every player in the industry — all of us have gotten it wrong. My sense is that we truly are at a low point. It's also been a lengthy stretch of decline, quarter after quarter. Whether we've hit the bottom, I can't say, but we're getting near it. What we can't say is when the recovery will begin. That's why I think we get the message. We want to be ready for whatever scenario. That's why, at the same time, we're really optimizing what's tied to cost, cash and so on, but not jeopardizing the ability to rebound when the cycle comes back. Your experience has been that every time the light has returned, we're among the first to take advantage of the recovery. We want to keep this mindset while recognizing the challenge of the current macro and adapting what we have to do, but without losing, I would say, the focus on Arkema's long-term development. It's a fine balance, but I think that's what we've tried to do so far.
Regarding PIAM, as you're aware, it's highly dependent on the end market—especially advanced electronics within PIAM. Quarter-to-quarter visibility can shift since it hinges on customer stock policy and similar factors. Overall, we've had a solid year and solid improvement for PIAM, with a margin of roughly, again, 30% in Q3, which shows PIAM's resilience well beyond any downturn in specialty chemicals. Those were fairly flat in Q3 following very robust growth in Q2. For now I don't want to discuss 2026, though on PIAM I can offer a brief remark. The outlook appears fairly favorable for 2026, both from what we see and from their conversations with customers. I'd say PIAM definitely fell short of its original business plan, yet proved quite resilient, expanding this year and looking rather positive for the next. On your final question, I think the challenge is, first, we're performing well on stock—you can see that in the cash generation. The trouble when you're midway through the year, particularly at the close of Q3, is that you're still at a stage where sales seasonality is fairly steady. You also can't run the risk of losing sales.
We're aware there are chances to bring our inventory down even more before the year is out, and we're going to make that happen — we know the way to get there. Marie-José, perhaps you'd like to add something?
Actually, Emmanuel, if you look at the inventory-to-sales ratio, honestly, we're pretty much in line. Compared with last year — at the close of last year, we ended at EUR 1,350,000, and that stood at 14.7% of our sales in terms of stock level. This year we're sitting at EUR 1,309,000, as you pointed out, which works out to 15% of our 12-month sales. In the end, since we're not yet at year-end, there's only a very limited amount, let's say, of excess stock in the chain relative to where we stood at last year's year-end. Without question, we keep adjusting to the forecast on an ongoing basis, and there's a further expected reduction for year-end on this particular metric.
All right, thanks so much.
James Hooper from Bernstein has the next question. Go right ahead.
Morning, and thanks so much for taking my questions. I have two, please. The first concerns the cost savings and the delivery. How does the increase square with the ambition you set out at the 2023 CMD of delivering EUR 250 million of savings across the five years? You've added the incremental EUR 50 million this year. Has the opportunity actually become EUR 50 million larger, or is this more about pulling savings forward to take advantage of the current situation? The second question is about the special necessity material projects. Initially, when you guided for 2025, you had EUR 100 million. They've been downgraded to EUR 60 million. What contribution to growth potential do you expect, assuming a similar macro environment in the years ahead? Put another way, if these projects have contributed EUR 60 million more and EBITDA is down EUR 250 million year-on-year, what actions are you taking for the rest of the business? Can these businesses grow fast enough to offset weakness elsewhere despite your cost savings? Thank you.
Alright. So on the extra cost savings — yes, obviously, what we're doing isn't only about getting faster on those savings. It's about adding to them. What that means is, if we take this year as an example and we go up by EUR 50 million, then that EUR 50 million is something you'll see at the close of the five-year period. So that puts us at EUR 300 million. And if next year, in order to offset inflation, we again come in well above EUR 50 million, that additional amount also sits on top of the EUR 300 million we just mentioned, and so on. Under no circumstances will we say up to EUR 50 million. In the end it will be far more than EUR 250 million. I think that answers your question. On project contribution, the growth potential for us remains intact. The question is more that it hinges on the macro scenario. It hinges on whether the macro recovers as soon as the course of next year or afterward, whatever it may be. What's clear is that we believe the figures we've shared with you are unchanged. It's more a matter of the timeline.
So that means if the macro recovers sooner rather than later, I believe we can definitely still aim for EUR 400 million in 2028. Should things take longer, hitting that EUR 400 million will be tough. I think the best approach would be to give an update at some point next year on all of these projects. What matters a great deal to me is that this project, from a strategic point of view, is — and to some degree it ties back to the answer I gave to the earlier question — the strategy behind this project remains entirely sound. Even though the world keeps shifting constantly, from what we observe in how the world is evolving, these projects are still fully relevant, and that is the key thing. We can now debate the timing — whether we can still hold to what we stated about reaching the EUR 400 million for 2028, or whether, if the macro stays as it is, as you pointed out, then naturally there will be some slippage. In the end, the contribution will still be quite substantial. The end result will be identical, obviously. Now, as we said, I'm not sure whether your question is really about additional action on the project.
Did you get that? No. Arkema’s efforts aren’t confined to this one project. We have many new businesses that have no connection at all to it. Obviously, if you look at something like the data center area we talked about — which wasn’t really on our radar until not long ago — that’s something we’ll grow. It won’t be tied to this major project. That’s a separate matter. We keep rounding out our pipeline for new business development as the world changes.
Jean-Luc Romain from CIC Market Solutions has the next question. Go right ahead.
Morning, everyone. I hope my voice is coming through more clearly at this point.
You'll need to speak up a bit. I'm not sure why, but it's coming through very quietly.
I've got a question about those 5 outlets that are growing at 20%. When you originally discussed those 5 sectors, they accounted for 50% of your sales, and your goal is 25%. At this point, what's the weight of those 5 outlets that are outpacing the rest of your business?
All right. If I've got the question right, that 20% growth is attributable to the five markets, which account for 15% of Arkema — but we aren't earning 20% across that entire 15%. It's a slice of the market we referenced earlier: batteries, sport, and so on. It sits within the five markets, within the five platforms. So that 20% really applies to roughly 7% of sales. On the remaining 8%, we're much more stable. Does that address your question?
Thanks a lot.
We’ll take the final question.
Gentlemen, at this point we have no further questions registered.
All right, then — if there are no further questions, I’d really like to thank you a lot for making the time to join us. That covers everything else, and I hope you have a good day. Please feel free to reach out again to Béatrice or to James should anything else come up. Thanks once more.
Ladies and gentlemen, that brings us to the end of this conference call. Arkema appreciates your taking part. You can disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Arkema S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Arkema S.A. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.